ARS Pharmaceuticals (SPRY) Preferred Stock Liabilities (2021)

ARS Pharmaceuticals (SPRY) reported Preferred Stock Liabilities of $19.9 million for Q4 2021.

ARS Pharmaceuticals (SPRY) Preferred Stock Liabilities (2021) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 1 years of Preferred Stock Liabilities data on file, last reported at $19.9 million in Q4 2021.

For the quarter ending Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $19.9 million; the trailing twelve-month figure through Dec 2021 stood at $19.9 million (changed N/A YoY), and the FY2021 full-year result was $19.9 million, changed N/A from the prior year.
Preferred Stock Liabilities was little changed at $19.9 million in Q4 2021.
In the past five years, Preferred Stock Liabilities ranged from a high of $19.9 million in Q4 2021 to a low of $19.9 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-	-

Download Data

Date	Value
Dec 31, 2021	19.87 Mn